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PVIEWPOINT AND COMMENTARY
Screen Testing
Cardiovascular Prevention in Asymptomatic Diabetic Patients
George A. Diamond, MD, FACC, Sanjay Kaul, MD, FACC, Prediman K. Shah, MD, FACC
Los Angeles, California
It has recently been proposed that asymptomatic diabetic patients undergo routine screening for subclinical ath-
erosclerotic disease using myocardial perfusion scintigraphy. We herein analyze the expected cost and benefit
associated with such a conditional test-treatment strategy (scintigraphic testing followed by statin treatment in
positive test responders) in comparison to an unconditional treatment strategy (no testing and statin treatment
in all). This analysis shows that unconditional treatment is the dominant strategy, costing 24% less ($3.2 billion)
and preventing 25% more (16,800) atherosclerotic events annually on a national basis. (J Am Coll Cardiol
2007;49:1915–7) © 2007 by the American College of Cardiology Foundation
ublished by Elsevier Inc. doi:10.1016/j.jacc.2006.09.057c
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tAll right, Mr. DeMille, I’m ready for my close-up.
Norma Desmond in Sunset Boulevard (1950) (1)
wo recent perspectives argue the pros (2) and cons (3) of
sing myocardial perfusion scintigraphy (MPS) as the basis
f a screening strategy to prevent atherosclerotic events in
symptomatic diabetic patients. However, although both
ssays allude to the importance of assessing the strategy’s
ost effectiveness, neither offers such an assessment. The
esultant analyses are therefore less than thorough, akin to
eporting the sensitivity of a diagnostic test, but not its
pecificity or the efficacy of a new drug, but not its safety.
Accordingly, our purpose is to take a more thorough
close-up” picture of this proposal. Toward that end, we
hall perform a simple back-of-the-envelope calculation of
he expected cost and benefit associated with the proposed
onditional test-treatment strategy (screen everyone with the
est, and treat only those with an abnormal response), and
ompare these expectations to those associated with an
lternative unconditional treatment strategy (test no one, and
reat everyone). Our analysis addresses only the proposal at
and, and is not intended as a comprehensive discourse on
he general process of epidemiologic screening, the princi-
les of which are discussed elsewhere (4,5).
The results of our calculations are summarized in Table 1.
ssume that the treatment is a preventive drug (a statin), at
cost of about $2 per day ($720 per year) based on 2006
verage wholesale prices (6), and assume further that the test
MPS) has a one-time technical and professional cost of
809—the national average Medicare reimbursement for
rom the Division of Cardiology, Cedars-Sinai Medical Center, Los Angeles,
alifornia; and the David Geffen School of Medicine, University of California,
os Angeles, California.m
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006, accepted September 19, 2006.urrent procedure terminology codes 78465, 78468, 78480,
nd 93015, comprising 22.37 relative value units (3) at a
onversion factor of $36.177 per unit under the 2006 Deficit
eduction Act (7). The cost of testing outside of the
edicare population, although generally higher, cannot be
stimated reliably.
In the absence of testing or treatment, we expect about
80,000 atherosclerotic events per year in the target adult
opulation of 14 million asymptomatic persons with diabe-
es not already known to have cardiovascular (CV) disease
3)—an event rate of 2% (twice that of the general popula-
ion) (8). If we treat every one of these adults, as prescribed
y the unconditional strategy, we can expect to reduce these
vents by about 30% based upon available randomized
linical trials (9,10). We thereby expect to prevent 84,000
vents (30% of 280,000) at a total cost of $10.1 billion
nnually ($720 per patient per year times 14 million
atients). Assuming that each event is equivalent to an
verage loss of 13 life-years (11), this represents a gain of
,092,000 life-years (84,000 events times 13 years per event)
nd a cost-effectiveness ratio of $9,249 per life-year ($10.1
illion divided by 1,092,000 life-years)—well within the
5,063 to $23,792 range reported in a recent formal analysis
12).
The alternative conditional strategy would have us test all
4 million individuals at $809 per patient and a cost of
11.3 billion. Although it has not been explicitly validated
n this context, Pareto’s 80/20 rule (13) is consistent with
he available data regarding screen testing of asymptomatic
iabetic patients (14–16). Based on this rule, we can project
hat our test will identify approximately 20% of the popu-
ation (2.8 million patients) among whom 80% of the events
ill occur (224,000 events)—an event rate of 8% (4 times
hat of the untested diabetic patients). This leaves 11.2
illion patients with a negative test, among which the
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cur (an event rate of 0.5%).
These values are consistent with
those in a number of empirical
studies regarding the screening
of asymptomatic diabetic pa-
tients (2,3).
If we now treat only the higher-risk population with a
ositive test, we can expect to prevent 67,200 events (30% of
24,000) at an overall cost of $13.3 billion ($11.3 billion for
esting plus $2 billion for treatment)—a gain of 873,600
ife-years (67,200 events times 13 years per event) and a
ost-effectiveness ratio of $15,224 per life-year ($13.3 bil-
ion divided by 873,600 life-years). The latter figure prob-
bly represents an underestimation as it ignores the added
osts associated with referral of some proportion of this
opulation for coronary angiography and myocardial revas-
ularization as a consequence of testing, procedures not
nown to provide any preventive benefit in asymptomatic
iabetic patients (17).
Thus, the unconditional treatment strategy dominates the
onditional test-treatment strategy because it costs at least
3.2 billion (24%) less and prevents at least 16,800 (25%)
ore events. A sensitivity analysis performed by varying the
ost of the statin from $0.50 to $2.50 per day and the cost
f MPS from $500 to $2,000 shows the annual cost
ifferential to range from $3 billion in favor of test treat-
ent (when testing costs $500 and treatment costs $2.50) to
26 billion in favor of treatment (when testing costs $2,000
nd treatment costs $0.50). No matter how we vary the
osts, however, unconditional treatment is still more effec-
ive than conditional testing, preventing 16,800 more events
er year. However, despite favorable cost-effectiveness ra-
ios, both strategies cost upwards of $10 billion annually
Table 1).
Less expensive alternative tests such as electron beam
omputed tomography (18) and high-sensitivity C-reactive
rotein (19) have been proposed as the basis for CV
creening, but would fare no better, even if they were more
ccurate. Thus, a screening strategy based on an imaginary
est costing only $20 and capable of identifying 10% of the
4 million diabetic patients experiencing 90% of the
Abbreviations
and Acronyms
CV  cardiovascular
MPS  myocardial
perfusion scintigraphy
nconditional Versus Conditional Strategiesor Cardiovascular Preve tion in Diabetic Patients
Table 1 Unconditional Versus Conditional Strategiesfor Cardiovascular Prevention in Diabetic Patients
Metric Treat Test ¡ Treat
Target population 14 million 14 million
Test population 0 14 million
Treatment population 14 million 2.8 million
Expected events 280,000 224,000
Testing cost $0 $11.3 billion
Treatment cost $10.1 billion $2.0 billion
Total cost $10.1 billion $13.3 billion
Prevented events 84,000 67,200
Cost/prevented event $120,238 $197,917v
Cost/life year $9,249 $15,22480,000 events in the year after testing (an event rate of 18%
n those testing positive vs. 0.2% in those testing negative,
nd an unprecedented risk ratio of 80:1) would still prevent
,400 fewer events than an unconditional treatment strat-
gy, even though it would cost $8.8 billion less. Under these
ircumstances, the most compelling argument one could
ount against the unconditional treatment strategy is that
he additional benefits might not be economically justified
having a marginal cost-effectiveness ratio of $80,586 per
ife-year). In the final analysis, although calls to perform
outcome studies” (2) and to somehow “enrich” the process
f screening (3) are well-intentioned, we cannot change the
imple fact that testing, per se, cannot prevent events. Only
reatment can do that. Because screen tests identify a
raction of the target population for treatment, they can
ower the cost of prevention, but because they fail to identify
ll who might benefit from treatment, they also lower the
ffectiveness of prevention.
In any case, it would be rather daunting to conduct a
linical trial of these strategies. Given the small difference in
rojected outcome (7.0% for unconditional treatment vs.
.6% for conditional testing over 5 years), a trial to prove the
uperiority of the former over the latter would require the
andomization of 80,000 subjects followed for 5 years
assuming no dropouts). It is doubtful, then, that strategies
uch as these will ever be prospectively validated.
Accordingly, we posit 3 questions based on accepted
rinciples of consumer protection that any responsible advocate
or preventive screening should be prepared to answer:
. How many people will it help? What is the additional
number of life-years saved, or events prevented, in the
target population? The greater its effectiveness, the
better the strategy.
. How much will it cost? What is the additional cost of the
strategy referenced to the entire target population? The
lower this cost, the better the strategy.
. How do you plan to pay for it given competing needs and
existing budgetary constraints?
These considerations are fully consistent with the letter and
he spirit of operative federal law governing Medicare’s regu-
atory policies, specifically, with Executive Order 12866 en-
cted by President Bill Clinton on September 30, 1993 (20):
In deciding whether and how to regulate, agencies should
assess all costs and benefits of available regulatory alterna-
tives, including the alternative of not regulating. Costs and
benefits shall be understood to include both quantifiable
measures (to the fullest extent that these can be usefully
estimated) and qualitative measures of costs and benefits
that are difficult to quantify, but nevertheless essential to
consider. Further, in choosing among alternative regulatory
approaches, agencies should select those approaches that
maximize net benefits. . .
roponents of global CV screening of asymptomatic indi-
iduals, diabetic patients or not, would be well advised to
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ough on your pocketbook and hazardous to your health
21).
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